Guardant Health's Blood Cancer Test Detects Early-Stage Colon Cancer

Results from a study by Guardant Health (NASDAQ:GH), presented at the American Association for Cancer Research Virtual Annual Meeting II, showed the company's Lunar-2 blood test can detect early-stage colon cancer.